HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Switch Of Kings? NZ Explores First-In-World Gout Medicine Rx-To-OTC Reclassification

Executive Summary

Could New Zealand become first country to switch gout medicine allopurinol from Rx to OTC status? HBW Insight speaks to applicant and global switch expert Natalie Gauld. 

You may also be interested in...

Industry Welcomes Australia’s OTC Drug Approach To Low-Dose CBD

Australia's Therapetics Goods Administration finalizes its decision to regulate low-dose CBD as an OTC medicine, raising the maximum daily dose to 150mg. The move is welcomed by the country's self-care industry. 

Global CBD Study Calls For Tighter Regulation And Clinical Trials

A wide-ranging study of low-dose cannabidiol supplementation, its regulation, efficacy and safety calls for improved legislation, guidelines and quality control together with clinical trials exploring the increasingly popular ingredient's therapeutic benefits.

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts